Sign up
Pharma Capital
Market: AIM
Sector: Pharma & Biotech
Market Cap: 4.16M

N4 Pharma was formed in 2014 by Nigel Theobald, the former chief executive of AIM-quoted Oxford Pharmascience Group PLC. N4 Pharma is a specialist pharmaceutical company that reformulates existing drugs and vaccines to improve their performance.

N4 Pharma’s reformulation work falls under two divisions:

1.generic, already commercialised, drugs; and of novel and existing...

N4 Pharma PLC

Interactive graph

col 3
col 4
col 5
col 6

N4 Pharma PLC RNS Announcements

Date Epic Announcement
19/06/2019 N4P Result of AGM
19/06/2019 N4P AGM Statement
14/06/2019 N4P Second Price Monitoring Extn
14/06/2019 N4P Price Monitoring Extension
28/05/2019 N4P Change to Director Shareholding
22/05/2019 N4P Posting of Annual Report and Notice of AGM
21/05/2019 N4P Board Changes
14/05/2019 N4P Final Results
15/04/2019 N4P Nuvec® Research update
10/04/2019 N4P Director/PDMR Shareholding
09/04/2019 N4P Nuvec® Research update
20/03/2019 N4P Holding(s) in Company
20/03/2019 N4P Holding(s) in Company
28/02/2019 N4P Total Voting Rights
14/02/2019 N4P Holding(s) in Company
08/02/2019 N4P Placing to raise £1.05 million
20/12/2018 N4P Nuvec licence extension
28/11/2018 N4P Nuvec® research update
16/11/2018 N4P Nuvec resource changes
15/11/2018 N4P Filing of further Nuvec® patent application

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.